araag2/HINT huggingface dataset:
Clinical trial NCT00616551 (phase 3, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: c2l-oct-01 pr, 30 mg, octreotide acetate prolonged release, 30 mg
SMILES: [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must be diagnosed with active acromegaly.

          -  If subject is treated with a long acting somatostatin analogue, the treatment must
             have been unchanged for a period of at least 12 weeks prior to entry.

          -  If subject is treated with a 30 mg dose of a depot formulation of a somatostatin
             analogue, the IGF-1 levels must be normal at entry.

          -  If subject is treated with a 20 mg dose of a depot formulation of a somatostatin
             analogue, any value of IGF-1 is acceptable.

          -  If the subject is receiving an immediate release formulation of a somatostatin
             analogue or a dopamine agonist, the IGF-1 values must be above 10% of the reference
             range based on gender and age.

          -  If the subject is receiving a dopamine agonist, it must be stopped 14 days prior to
             receiving the study medication.

          -  The subject should be able to understand the instructions, provide a written consent
             and abide by the study restrictions.

        Exclusion Criteria:

          -  Women of childbearing potential who are not taking adequate contraception or who are
             pregnant or lactating.

          -  Subjects previously treated with a growth hormone receptor antagonist (Pegvisomant)
             within 12 weeks of study entry.

          -  Subjects who have undergone pituitary surgery within 6 months or radiotherapy within 2
             years prior to admission into the study

          -  Subjects who present some form of intolerance or allergy to the test article or one of
             its non-active ingredients

          -  Subject who have any other condition that alters the growth hormone or IGF-1 levels.

          -  Subjects with signs or symptoms related to a tumor compression of the optical chiasm.
Clinical trial NCT00371137 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: xyrem®, placebo
SMILES: [Na+].OCCCC([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects, 18 years or older who meet the American College of
             Rheumatology (ACR) diagnostic criteria for fibromyalgia.

        Exclusion Criteria:

          -  Subjects will be excluded if they have a history of rheumatic disease or other
             disorders that may compromise reliable representation of subjective symptoms.

          -  Any other condition that will cause a risk to subjects if they participate in the
             trial is also a reason for exclusion.
Clinical trial NCT00269776 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: placebo, oros (methylphenidate hcl), ritalin (methylphenidate)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)C(C1CCCCN1)C1=CC=CC=C1, COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients having a diagnosis of one of the three subtypes of Attention Deficit
             Hyperactivity Disorder (ADHD) verified by both a parent/child interview and a teacher
             assessment using SNAP-IV questionnaires

          -  taking or have taken in the past 5 - 20 mg of immediate-release methylphenidate
             (Ritalin) at least twice a day, 20 - 60 mg of sustained-release methylphenidate
             (Ritalin-SR) per day, or a combination of immediate-release and sustained-release
             methylphenidate up to a daily dose not exceeding 60 mg

          -  having used methylphenidate for at least 3 months at some time in the past without any
             significant adverse experiences, considered to be positive responders to
             methylphenidate therapy, and agreeing to take to take only the supplied study drug as
             treatment for ADHD during the three-week treatment phase of the study

          -  able to comply with the study visit schedule and whose parent(s) and teacher are
             willing and able to complete the protocol-specified assessments

          -  agreeing not to ingest any caffeine containing beverages (e.g., coffee or soda) or
             foods (e.g., chocolate) on days 7, 14, and 21 of the study.

        Exclusion Criteria:

          -  Patients having clinically significant gastrointestinal problems, including narrowing
             of the gastrointestinal tract

          -  having glaucoma, an ongoing seizure disorder, a psychotic disorder, or have a
             diagnosis of Tourette's syndrome

          -  whose primary treatment focus is oppositional-defiant disorder, conduct disorder, or
             tics, or whose primary treatment focus is psychiatric conditions such as depressive
             disorders, bipolar disorders, or other mood disorders

          -  having a mean of two blood pressure measurements (systolic or diastolic) equal to or
             greater than the 95th percentile for age, sex, and height at screening

          -  if female, have begun menstruation.
Clinical trial NCT00627926 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: telaprevir, ribavirin
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria

          -  Has not received any previous treatment with any approved or investigational drug or
             drug regimen for the treatment of hepatitis C

          -  Male and female subjects, 18 to 70 years of age, inclusive

          -  Genotype 1, chronic hepatitis C with detectable Hepatitis C Virus (HCV) Ribonucleic
             Acid (RNA)

          -  Screening laboratory values, tests, and physical exam within acceptable ranges

          -  Able and willing to follow contraception requirements

          -  Able to read and understand, and willing to sign the informed consent form and abide
             by the study restrictions

        Exclusion Criteria

          -  Subject has any contraindications to Pegasys® or Copegus® therapy

          -  Evidence of hepatic decompensation in cirrhotic subjects

          -  History of organ transplant

          -  History of, or any current medical condition which could impact the safety of the
             subject in participation in the study
Clinical trial NCT01309542 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: desvenlafaxine succinate
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients who have completed double-blind therapy in a phase 3 DVS-233 SR short-term
             study for the indication of MDD, including scheduled evaluations, with no major
             protocol violations and no study events that, in the opinion of the investigator,
             would preclude the subject's entry into the long-term, open-label study.

          -  Sexually active individuals participating in the study must use a medically acceptable
             form of contraception during the trial and for at least 15 days after the last dose of
             study drug.

        Exclusion Criteria:

          -  Clinically important abnormalities on baseline physical examination, or any unresolved
             clinically significant abnormalities on ECG, laboratory test results, or vital signs
             recorded in a previous phase 3 DVS-233 SR short-term study for the indication of MDD.
             Any exception must be discussed with and granted by the sponsor.

          -  Significant risk of suicide based on clinical judgment, including common suicidal
             thoughts, and suicide being considered as a possible solution, even without specific
             plans or intention.

          -  Presence of clinically important hepatic or renal disease or other medical disease
             that might compromise the study or be detrimental to the subject (eg, clinically
             important cardiac arrhythmia, uncontrolled diabetes, uncontrolled hypertension,
             seizure disorder, myocardial infarction, neurologic disorder, acute illness,
             neoplastic disorder).
Clinical trial NCT00294515 (phase 3, status: completed)
Conditions: cytomegalovirus infections
ICD codes: P35.1
Drugs: valganciclovir, valganciclovir
SMILES: CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O, CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 16 years of age

          -  CMV seronegative recipient of primary or secondary renal allograft from a living or
             cadaveric seropositive donor

          -  Adequate hematological and renal function

          -  Patients and partners must agree to maintain effective birth control for 90 days
             following cessation of study medication

        Exclusion Criteria:

          -  CMV disease, or receipt of anti-CMV therapy within 30 days prior to screening

          -  Multi-organ transplant recipient

          -  Hepatitis B, hepatitis C or HIV positive

          -  Women who are pregnant or lactating
Clinical trial NCT00448578 (phase 3, status: completed)
Conditions: mania, bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: quetiapine fumarate, lithium
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, [Li+]
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent for study participation, signed by the patient's legal
             guardian.

          -  Both at screening and at randomization (Day 1), had a YMRS total score of at least 20.

        Exclusion Criteria:

          -  Known intolerance or lack of response to quetiapine or lithium, as judged by the
             investigator.

          -  Known or suspected hypersensitivity to quetiapine or lithium.
Clinical trial NCT01499368 (phase 3, status: completed)
Conditions: erosive esophagitis
ICD codes: B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: lafutidine, famotidine, omeprazole
SMILES: [H]\C(COC1=NC=CC(CN2CCCCC2)=C1)=C(/[H])CN=C(O)CS(=O)CC1=CC=CO1, NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1, [Na+].OC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux
             esophagitis according to the Los Angeles classification

        Exclusion Criteria:

          -  Gastric or duodenal ulcers (excluding ulcer scars)

          -  Concurrent presence of Barrett's esophagus

          -  A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks

          -  Other conditions considered by the attending physician to potentially affect the
             assessment of efficacy and safety
Clinical trial NCT00416520 (phase 3, status: completed)
Conditions: chronic kidney disease, hyperphosphatemia
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: mci-196 (colestilan(inn), colestimide(jan), cholebine®), placebo, another phosphate binder (sevelamer)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years of age or over

          -  Clinically stable haemodialysis or peritoneal dialysis

          -  Stable phosphate control

          -  On a stabilised phosphorus diet

          -  Female and of child-bearing potential have a negative serum pregnancy test.

          -  Male subjects must agree to use appropriate contraception.

        Exclusion Criteria:

          -  Current clinically significant medical comorbidities, which may substantially
             compromise subject safety, or expose them to undue risk, or interfere significantly
             with study procedures and which, in the opinion of the Investigator, makes the subject
             unsuitable for inclusion in the study.

          -  Body Mass Index (BMI) <=16.0 kg/m2 or >=40.0 kg/m2

          -  A current or history of significant gastrointestinal motility problems

          -  A positive test for HIV 1 and 2 antibodies

          -  A history of substance or alcohol abuse within the last year.

          -  Seizure disorders

          -  A history of drug or other allergy

          -  A temporary catheter as a vascular access

          -  Participated in a clinical study with any experimental medication in the last 30 days
             or an experimental biological product within the last 90 days prior to signing of
             informed consent
Clinical trial NCT00483548 (phase 3, status: completed)
Conditions: bipolar disorder, depression, bipolar
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: ziprasidone, placebo
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
             (DSM-IV) criteria for Bipolar I disorder, most recent episode depressed, with or
             without rapid cycling and without psychotic features. Subjects receive therapeutic
             dose of lithium, valproate or lamotrigine for at least 4 weeks prior to randomization.

        Exclusion Criteria:

          -  Patients with ultra-fast rapid cycling (8 or more mood episodes per year)

          -  Significant heart disease including abnormalities in the heart's rhythm (QT
             prolongation)

          -  Psychotic symptoms (hallucinations and/or delusions).
Clinical trial NCT00110162 (phase 3, status: unknown status)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: antiandrogen therapy, releasing hormone agonist therapy
SMILES: CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Prostate-specific antigen (PSA) relapse OR incurable disease diagnosed within the past
             2 months AND meets criteria for either of the following groups:

               -  Group 1

                    -  In PSA relapse after definitive radical treatment (prostatectomy or
                       radiotherapy), as evidenced by 1 the following:

                         -  Post-prostatectomy PSA level ≥ 0.2 ng/mL

                         -  At least 3 rising PSA levels (post-radiotherapy) obtained ≥ 1 month
                            apart, with the last PSA obtained within the past 2 months

                    -  No metastatic disease by bone scan or abdomino-pelvic CT scan

               -  Group 2

                    -  Not suitable for radical treatment at primary diagnosis

                    -  Not planning to receive curative treatment

                    -  Localized or metastatic disease

                         -  No symptomatic disease requiring radiotherapy or immediate hormonal
                            therapy

          -  No symptomatic disease requiring therapy

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  Not specified

        Life expectancy

          -  At least 5 years

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  No other significant comorbid condition that would limit life expectancy to < 5 years

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  At least 12 months since prior androgen deprivation therapy (ADT) administered in the
             neoadjuvant or concurrent (with radiotherapy) setting (group 1)

          -  No prior ADT (group 2)

        Radiotherapy

          -  See Disease Characteristics

          -  See Endocrine therapy

        Surgery

          -  See Disease Characteristics

        Other

          -  No concurrent enrollment in TROG-96.01 or TROG-RADAR protocols
Clinical trial NCT00646542 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History T2DM

          -  Moderate or Severe Renal Impairment

        Exclusion Criteria:

          -  Glucose > 270 mg/dL (>15 mmol/L)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01165281 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oxycodone cr, r331333 (referred to as jns024 er or cg5503)
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Documented clinical diagnosis of any type of cancer

          -  Diagnosis of chronic malignant tumor-related cancer pain with an average score for
             pain intensity in the past 24 hours of >=4 on the 11-point numerical rating scale
             (NRS) on the day of randomization (Day -1)

          -  Have not received treatment with opioid analgesics within 28 days before screening
             (Note: codeine phosphate [<=60 mg/d] or dihydrocodeine phosphate [<=30 mg/d] for
             antitussive use are allowed)

          -  Dissatisfied with pain relief by the current treatment and for whom the investigator
             or designee judges that treatment with opioid analgesics is required

        Exclusion Criteria:

          -  Have complicated with uncontrolled/clinically significant arrhythmia

          -  Have previous or concurrent presence of any disease which may develop increased
             intracranial pressure, disturbance of consciousness, lethargy, or respiratory problems
             such as traumatic encephalopathy with cerebral contusion, intracranial hematoma,
             disturbance of consciousness, brain tumor, cerebral infarction, transient ischemic
             attack, epilepsy or convulsive diseases

          -  Have history of alcohol and/or drug abuse

          -  Have any disease for which opioids are contraindicated such as serious respiratory
             depression of serious chronic obstructive pulmonary disease, bronchial asthma attack,
             cardiac failure secondary to chronic pulmonary disease, paralytic ileus, status
             epileptics, tetanus, strychnine poisoning, acute alcohol poisoning, hypersensitivity
             to opium alkaloid, hemorrhagic colitis, or bacterial diarrhea
Clinical trial NCT00097786 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: valsartan 160 mg + nateglinide 60 mg, valsartan 160 mg + nateglinide placebo, nateglinide 60 mg + valsartan placebo, valsartan placebo + nateglinide placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, [H][C@](CC1=CC=CC=C1)(N=C(O)[C@@]1([H])CC[C@@]([H])(CC1)C(C)C)C(O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults

          -  Impaired glucose tolerance

          -  Age dependent risk factors

        Exclusion Criteria:

          -  Frank diabetes

        For detailed information, call contact person.
Clinical trial NCT00419744 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: budesonide/formoterol (symbicort) pmdi, formoterol turbuhaler
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  A current clinical diagnosis of COPD with COPD symptoms for more than 2 years

          -  Current smoker or smoking history of 10 or more pack years (1 pack year = 20
             cigarettes smoked per day for one year)

          -  A history of at least 1 COPD exacerbations requiring a course of steroids and/or
             antibiotics within 1-12 months before the first visit

        Exclusion Criteria:

          -  A history of asthma at or after 18 years of age

          -  A history of allergic rhinitis at or after 18 years of age

          -  Subjects taking oral steroids

          -  Any significant disease or disorder that may jeopardize a subject's safety
Clinical trial NCT00349375 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: fenofibrate/simvastatin, fenofibrate/simvastatin, simvastatin
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Mixed dyslipidemia

        Exclusion Criteria:

          -  Known hypersensitivity to fenofibrate or simvastatin

          -  Pregnant or lactating women

          -  Contra-indication to fenofibrate or simvastatin

          -  Unstable or severe cardiac disease